Tango and Erasca’s Phase I/II trial of ERAS-0015 combo opens for enrolment

Tango Therapeutics and Erasca began a Phase I/II trial for ERAS-0015 and vopimetostat combo in lung and pancreatic cancer patients. The trial, sponsored by Tango, aims to find the max tolerated dose and assess safety, tolerability, and antitumour activity. Both companies believe the combo shows promise in treating RAS-driven cancers. ERAS-0015 targets RAS signalling, while vopimetostat inhibits PRMT5.

Original reporting
Published Nov 5, 2026, 9:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$ERAS
Relevance
7/10
AlphAI data visualization · based on clinicaltrialsarena.com
Decision brief

The 30-second read

Low
01

Why it matters

The trial start signals progress for both companies' pipelines but provides no immediate financial impact. Investors may watch for future data releases.

02

Market read

Early‑stage clinical trial initiation; limited immediate market effect but potential long‑term relevance for oncology biotech sector.

03

What to watch

Potential competition in RAS‑targeted therapies and regulatory timelines.

Relevance 7/10Novelty 7/10Timing: announcement today

Background

Tango Therapeutics and Erasca have opened enrolment for a Phase I/II trial of their combined oral therapies ERAS-0015 and vopimetostat in MTAP‑deleted pancreatic and RAS‑mutant lung cancers.

Market effects

None

None

None

Counterpoint

No clear contrarian angle; early trial data could be delayed or negative.

Key entities

  • Tango Therapeutics

    Biotech firm developing the PRMT5 inhibitor vopimetostat.

  • Erasca

    Biotech firm developing the pan‑RAS molecular glue ERAS‑0015.

Related articles

$ERASHighAI 8/10

FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage

Erasca (ERAS) received FDA Fast Track Designation for ERAS-0015, an oral pan-RAS molecular glue, for metastatic pancreatic cancer. The designation allows for accelerated regulatory review. In a Phase 1 trial, ERAS-0015 showed a 57% response rate in pancreatic cancer patients. The company plans to initiate pivotal trials in 2027. Q2 2026 R&D expenses rose to $35.9M, and net loss widened to $44.1M. Erasca raised $632.5M in July 2026, leaving it with $384.3M in cash.

$ERASHighAI 8/10

ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death

Erasca, Inc. (ERAS) shares dropped nearly 40% after-hours following a treatment-related death in a Phase 1 study of its cancer therapy ERAS-0015, despite positive early tumor response rates. The patient, a 66-year-old with pancreatic cancer, died after developing pneumonitis. The company reported strong response rates in lung and pancreatic cancers and plans to advance to expansion studies. Additionally, Erasca faces patent infringement allegations from Revolution Medicines regarding ERAS-0015.